Aviragen Therapeutics' P2P Acquisition

Aviragen Therapeutics raised a round of funding on January 12, 2018. Investors include Vaxart.

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients glob…

Articles about Aviragen Therapeutics' P2P Acquisition: